AnaptysBio Inc (ANAB)
21.30
-0.19
(-0.88%)
USD |
NASDAQ |
Nov 08, 16:00
21.30
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Revenue (TTM): 57.17M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 57.17M |
| June 30, 2024 | 30.47M |
| March 31, 2024 | 22.96M |
| December 31, 2023 | 17.16M |
| September 30, 2023 | 14.96M |
| June 30, 2023 | 12.94M |
| March 31, 2023 | 10.69M |
| December 31, 2022 | 10.29M |
| September 30, 2022 | 4.49M |
| June 30, 2022 | 24.09M |
| March 31, 2022 | 52.90M |
| December 31, 2021 | 63.18M |
| September 30, 2021 | 122.16M |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 16.68M |
| September 30, 2016 | 17.98M |
| June 30, 2016 | 19.31M |
| March 31, 2016 | 18.34M |
| December 31, 2015 | 17.57M |
| September 30, 2015 | 17.22M |
| June 30, 2015 | 18.84M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
4.49M
Minimum
Sep 2022
122.16M
Maximum
Sep 2021
34.11M
Average
22.96M
Median
Mar 2024
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Regeneron Pharmaceuticals Inc | 13.85B |
| Ligand Pharmaceuticals Inc | 133.48M |
| Agios Pharmaceuticals Inc | 32.87M |
| ADMA Biologics Inc | 330.24M |